Red zone cash

Celldex Therapeutics Inc. (NASDAQ:CLDX) took advantage of recent share price gains to raise $103.5 million last week, the largest follow-on this year among companies valued below $500 million.

Celldex sold 13.8 million shares, including the overallotment, at $7.50. The price was a 1% premium to the company's $7.24 close on Feb. 4, when it proposed to raise $75 million. The financing tops the $80.4 million raised by renal disease play Keryx Biopharmaceuticals Inc. (NASDAQ:KERX), which had been the largest follow-on in the tier...